For busy parents juggling work and family life, supporting the development of a child with a cochlear implant can be a challenge.
But for UK parents Aman and Sukhvans Sandhu, adopting the latest technology and understanding how to get the most out of it is playing a significant role in helping them to support their 16-month-old son Arjan who has bilateral cochlear implants.
Using the Nucleus® Smart App, Aman and Sukhvans can access Arjan’s personalised hearing information from his CochlearTM Nucleus® 7 Sound Processors and monitor how much hearing practise Arjan has had during the day.
'We use the Smart App daily. Our favourite part is the app’s “Hearing Tracker”, as it gives us an indicator of how much varying sound Arjan is experiencing and how much time in speech he has,’ says his mother, Aman.
'Because we both work the Smart App is invaluable. It keeps a record, no matter what Arjan is doing or who he is with. When he’s been at a nursery, for example, we can check the Smart App to see how much time in speech he has had. And we can adapt the evening or make plans for the next day if we need to give him more time in a particular listening environment.'
'We make sure he has plenty of time on air every day - at least three to four hours in speech. So, we have a routine at home to make sure that happens,' she says.
Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always follow the directions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.
Views expressed are those of the individual. Consult your health professional to determine if you are a candidate for Cochlear technology.
In Australia, Cochlear™ Nucleus® implant systems are intended for the treatment of moderately severe to profound hearing loss.
In Australia, Baha® bone conduction implant systems are intended for the treatment of moderate to profound hearing loss.
In Australia, the Cochlear™ Osia® System is indicated for patients with conductive, mixed hearing loss and single-sided sensorineural deafness (SSD) aged 10 years and above with up to 55 decibels sensorineural hearing loss. Patients should have sufficient bone quality and quantity to support successful implant placement. Surgery is required to use this product. Any surgical procedure carries risk.
For Cochlear™ Nucleus®, Osia® and Baha® systems: This product is not available for purchase by the general public. For information on funding and reimbursement please contact your health care professional.
Any testimonial featured on this website is intended for an Australian audience only.